Toggle Main Menu Toggle Search

Open Access padlockePrints

The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine

Lookup NU author(s): Dr Fiona Douglas, Professor David Neal



Background: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk. Methodology/Principal Findings: MSMB expression in benign and malignant prostate tissue was examined using immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of MSMB staining and loss of MSMB in both tissue and urine in benign prostate. Conclusions: These data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB for a biomarker of prostate cancer risk, diagnosis and disease monitoring. Copyright: © 2010 Whitaker et al.

Publication metadata

Author(s): Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman G, Evans D, Blanco I, Mercer C, Rubinstein W, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D, Cooper C, Eeles R, Neal D

Publication type: Article

Publication status: Published

Journal: PLoS ONE

Year: 2010

Volume: 5

Issue: 10

Print publication date: 13/10/2010

Date deposited: 11/05/2011

ISSN (electronic): 1932-6203

Publisher: Public Library of Science


DOI: 10.1371/journal.pone.0013363


Altmetrics provided by Altmetric


Funder referenceFunder name
Biomedical Research Centre at Central Manchester Foundation Trust
Bio-medical Research Centre at The Institute of Cancer Research
Cambridge Bio-medical Research Centre, Cambridge, UK
Cancer Councils of Victoria and South Australia
Everyman Campaign
Institute of Cancer Research
NorthShore University Health System
Prostate Cancer Research Foundation
National Cancer Institute
Prostate Cancer Foundation of Australia
Ronald and Rita McAulay Foundation
Royal Marsden NHS Foundation Trust
20095Swedish Research Council (Medicine)
3455Swedish Cancer Society
C522/A8072University of Cambridge, Cancer Research UK
C5047/A8385University of Cambridge, Cancer Research UK
G0500966/75466National Cancer Research Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT)